Neuren Pharmaceuticals Shares Extend Slide on European Setback

Neuren Pharmaceuticals shares (ASX: NEU) have suffered a punishing decline that accelerated this week, with the biotech company’s regulatory challenges in Europe and ongoing concerns about its U.S. partner weighing heavily on market sentiment as the stock surrenders more than A$900 million in market capitalisation.

The Neuren Pharma share price closed 9.97% lower at A$14.63 on the day, marking the worst performance on the ASX 200 index, extending a brutal run for the stock, which has now fallen 22.63% since the start of 2026. Looking back to the end of October 2025, the damage is even more severe, with shares down 36% from highs as markets reassess the commercial prospects for the company’s key treatments and partnership arrangements after an earlier run up.

The sustained selling pressure has erased significant shareholder value, with the company’s market capitalisation contracting by more than A$900 million from its late October peak. Trading volumes have remained elevated throughout the decline, suggesting broad-based selling rather than isolated profit-taking.

What Happened Today?

The latest leg down in Neuren’s share price followed a critical regulatory setback in Europe. News came through that the European Medicines Agency’s Committee for Medicinal Products for Human Use delivered a negative trend vote on Acadia Pharmaceuticals’ marketing authorization application for trofinetide, a treatment for Rett syndrome. The decision represents a significant blow to Neuren’s expansion strategy, as European approval would unlock a substantial additional market for the therapy.

Neuren CEO Jon Pilcher expressed frustration over the CHMP decision and indicated support for Acadia’s plan to request a re-examination. The final outcome is expected upon formal adoption of the CHMP decision later in February, leaving markets in a state of uncertainty about the European pathway.

The European setback compounds existing concerns about Neuren’s partnership with Acadia Pharmaceuticals, which markets trofinetide as Daybue in the United States. In March 2024, short seller Culper Research released a report alleging that Acadia misrepresented safety data and patient retention rates for the drug, describing it as a “total flop.” While Acadia disputed these claims, the allegations have cast a shadow over the partnership’s credibility.

Commercial performance has also fallen short of initial expectations. In August 2024, Neuren entered a trading halt following a downgrade in full-year sales guidance for Daybue. Acadia lowered its FY24 sales forecast to between US$340 million and US$370 million, representing an 11% reduction at the midpoint. The revision was attributed to slower-than-expected patient additions, raising questions about market penetration and the therapy’s competitive positioning.

Adding to market unease, CEO Jon Pilcher sold 398,207 shares to institutional investors in September 2025 after repaying a $2.8 million loan attached to 1.5 million Loan Funded Shares. While the transaction improved Neuren’s cash position and eliminated the loan obligation, the timing of the sale may have been interpreted by some market participants as a signal about near-term prospects.

Outlook and Analysis

Despite the accumulation of negative news flow, not all analysts have abandoned Neuren. In June 2025, Macquarie initiated coverage with an ‘outperform’ rating and a price target of A$18.60, representing potential upside of more than 27% from current levels. The firm highlighted Neuren’s partnership with Acadia and the potential of its pipeline product, NNZ-2591, as key advantages that could drive future value creation.

The re-examination process at the EMA represents a critical near-term catalyst. A reversal of the negative trend vote could provide meaningful relief to the battered share price and restore confidence in the European expansion strategy. Conversely, confirmation of the rejection would likely trigger further selling and force a reassessment of revenue projections.

The development timeline for NNZ-2591, Neuren’s pipeline candidate targeting multiple rare pediatric conditions, may become increasingly important to the investment thesis if near-term headwinds persist for trofinetide. Positive clinical data or partnership announcements for NNZ-2591 could provide a separate value driver independent of current commercial challenges.

Neuren Pharmaceuticals faces a critical period as it navigates European regulatory uncertainty, works to rebuild confidence in its U.S. partnership, and attempts to demonstrate commercial traction for its lead therapy. While the stock’s 33% decline from October highs reflects genuine setbacks and execution challenges, the company retains assets and partnerships that could support a recovery if key catalysts break favourably in the months ahead. Despite what has been a tough time for bulls, the share price remains 7% higher on a rolling 12 month basis, and 888% higher over the past 5 years, with long-term holders likely to have a different view from those who have entered more recently.